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Abstract
Lung inflammation contributes to the pathogenesis of bronchopulmonary dysplasia (BPD) and
may be accompanied by a systematic inflammatory response. The objective of this study was to
investigate the role of systemic inflammation in the development of BPD in a cohort of extremely
low gestational age newborns (ELGANs) by examining the relationships between inflammation-
associated proteins in neonatal blood samples and pulmonary outcomes. Proteins were measured
in blood specimens collected on postnatal days 1–3, 5–8 and 12–15 from 932 ELGANs. Increased
risk of BPD was associated with elevated blood concentrations of a variety of pro-inflammatory
cytokines, adhesion molecules and proteases. Reduced risk was prominently associated with
increased concentrations of one chemokine, RANTES. Elevations of inflammatory proteins
associated with BPD risk occurred during the first days following birth, and inflammation
intensified thereafter. Therefore, exposures that promote inflammation after the first postnatal days
may be more critical in the pathogenesis of BPD. Fetal growth restriction, a known BPD risk
factor, was not accompanied by proteins elevations and therefore does not appear to be mediated
by systemic inflammation. By contrast, mechanical ventilation altered protein levels and may be
associated with systemic inflammation.
Introduction
Support for the claim that early postnatal inflammation contributes to the pathogenesis of
bronchopulmonary dysplasia (BPD) comes from several sources. First, the number of
inflammatory cells in the airways of preterm infants increases during acute lung disease, and
this increase persists in infants who develop BPD (1, 2). Second, preterm infants who
develop BPD are more likely than their peers to have elevated concentrations of
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inflammatory mediators in their tracheal fluid (3, 4). Finally, in animal models, exposures
associated with BPD (e.g. mechanical ventilation and increased ambient oxygen) increase
gene expression of inflammation-associated proteins and increase levels of these proteins in
the lung (5, 6).
The finding of altered levels of inflammation-associated proteins in the blood of infants who
develop BPD (7, 8) indicates that BPD may be associated with a systemic inflammatory
response, but it is not clear if these proteins originate in the lung or elsewhere. In either case,
measurement of biomarkers of inflammation in the blood may provide insight about the role
of inflammation in the development of BPD.
The objective of this study was to investigate the role of inflammation in the development of
BPD in a cohort of extremely low gestational age newborns (ELGANs) by examining the
relationships between biomarkers in neonatal blood samples and pulmonary outcomes. We
measured biomarker levels in serial blood specimens collected soon after birth and during
the subsequent two weeks. Our goal was to investigate the role of inflammation before and
following neonatal exposures that might promote inflammation. Of particular interest were
changes in levels of biomarkers among infants with factors known to increase the likelihood
of BPD, including fetal growth restriction and mechanical ventilation. Identifying
relationships between these risk factors and specific biomarkers might suggest mechanisms
through which these exposures impart risk. We examined these relationships separately in
infants with mild/moderate and severe BPD to evaluate the possibility that the
pathophysiology and the role of inflammation might be distinct in these two entities.
Methods
This study was a component of the ELGAN Study, a multi-center study designed to identify
characteristics and exposures that increase the risk of neurologic disorders in ELGANs (9).
During the years 2002–2004, women delivering before 28 weeks gestation at one of 14
institutions were enrolled in the study. The study was approved by the individual
institutional review boards, and informed consent was obtained from participating mothers.
The original consent and approval included the provision for secondary analyses of de-
identified data.
Our study cohort consisted of all infants in the ELGAN Study who survived to 36 weeks
postmenstrual age (PMA) for whom protein measurements were available in one or more
blood specimens obtained during the first two postnatal weeks. Because of financial
constraints, measurement of proteins was limited to specimens from infants who survived
until the 24-months adjusted age and for whom all elements of the follow-up evaluation at
24 months were completed, including developmental testing, neurologic examination and
measurement of head circumference. A full description of the methods of the ELGAN Study
is provided elsewhere (9). Here we focus on those most relevant to this report.
Maternal, Pregnancy and Newborn Variables
Selected characteristics of the pregnancy, intrapartum and newborn period were recorded.
The gestational age (GA) estimates were based on a hierarchy of the quality of available
information, that included (in order of priority): 1) dates of embryo retrieval or intrauterine
insemination or fetal ultrasound before the 14th week (62%), 2) fetal ultrasound at 14 or
more weeks (29%), 3) last menstrual period without fetal ultrasound (7%), and 4) GA
recorded in the log of the NICU (1%). The birth weight birth weight Z-score for each infant
was calculated using a standard data set (10).
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Data describing the highest level of respiratory support, categorized as no support, increased
ambient oxygen, nasal continuous positive airway pressure, conventional mechanical
ventilation or high frequency ventilation, was collected daily during the first week and on
days 7, 14, 21, and 28, and at 36 weeks PMA. We did not record the specific devices used.
BPD was defined as oxygen therapy at 36 weeks PMA. Decisions to administer
supplemental oxygen were made by infants’ clinical providers and were not based on a
uniform threshold of blood oxygenation. We subdivided these infants into those who were
not ventilator dependent (mild/moderate BPD) and those who were ventilator dependent
(severe BPD).
Placenta Morphology
Samples were collected from placentas for histologic examination, and were processed for
morphologic assessment as part of routine clinical care. Details describing the criteria for
each histologic lesion are presented elsewhere (11).
Blood Collection and Protein Measurements
Blood was collected on filter paper (Schleicher & Schuell 903). The times of collection are
designated as Day 1, 7 and 14, and were defined by the following ranges of postnatal age at
collection: Day 1 range = Days 1–3; Day 7 range = Days 5–8; Day 14 range = Days 12–15.
Dried blood spots were stored at −70°C in sealed bags with desiccant until processed.
Analyses of proteins were performed in the Laboratory of Genital Tract Biology, Brigham &
Women’s Hospital. For protein elution, 12mm punched biopsies of the frozen blood spots
were submerged in 300 µL PBS containing 0.1% Triton X100 (Sigma-Aldrich, St. Louis,
MO) and 0.03% Tween-20 (Fisher, Hampton, NH), vortexed for 30 seconds, and incubated
on a shaker for 1 hour at 4°C. The buffer and biopsy were then transferred over the filter of a
SpinX tube (Corning Fisher), centrifuged at 2000 × g followed by collection of the filtered
eluted blood. An additional wash of the punch was performed in 100 µL for a final elution
volume of 400 µL.
Proteins were measured in duplicate using the Meso Scale Discovery multiplex platform and
Sector Imager 2400 (MSD, Gaithersburg, MD). This electrochemiluminescence system has
been validated by comparisons with traditional ELISA (12). The MSD Discovery
Workbench Software was used to convert relative luminescent units into protein
concentrations using interpolation from several log calibrator curves. Split quality control
blood pools tested on each plate showed inter-assay variation of 10–20% for each protein.
The total protein concentration in each eluted sample was determined by BCA assay
(Thermo Scientific, Rockford, IL) using a multi-label Victor 2 counter (Perkin Elmer,
Boston, MA) and the measurement of each analyte was normalized to mg total protein.
We measured the following 25 proteins: IL-1β, IL-6, IL-6R (R=receptor), TNF-α, TNF-R1,
TNF-R2, IL-8 (CXCL8; interleukin-8), MCP-1 (CCL2; monocyte chemotactic protein-1),
MCP-4 (CCL13; monocyte chemoattractant protein-4), MIP-1β (CCL4; macrophage
inflammatory protein-1β), RANTES (CCL5; regulated upon activation, normal T-cell
expressed, and secreted), I-TAC ( CXCL11; interferon-inducible T cell alpha-
chemoattractant), ICAM-1 (CD54), ICAM-3 (CD50), VCAM-1 (CD106; vascular cell
adhesion molecule-1), E-selectin (CD62E; E-SEL), MMP-1 (matrix metalloproteinase-1),
MMP-9 (matrix metalloproteinase-9), CRP (C-reactive protein), SAA (serum amyloid A),
MPO (myeloperoxidase), VEGF, VEGF-R1, VEGF-R2, and IGFBP-1 (insulin growth factor
binding protein-1).
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We evaluated the generalized null hypothesis that the risks of mild/moderate and severe
BPD are not associated with blood protein concentrations in the highest quartile for GA and
the day the blood was collected. We began our analyses by exploring the frequency of each
entity in the four quartiles of the concentration of each protein. Linear trends were rare so
our final analyses are limited to comparisons of infants whose protein concentration was in
the highest quartile to infants whose protein concentration was in the lower three quartiles.
An association of risk of each BPD entity with a protein concentration in the highest quartile
was defined by an odds ratio and the 99% confidence interval. We selected this confidence
interval rather than the conventional 95% confidence interval because we wanted to modify
our analyses for multiple comparisons, while not appreciably increasing the risk of a type 2
error (13).
Because the two BPD entities are mutually exclusive and each is compared to the same
referent group (infants who did not develop BPD), we used multinomial logistic regression
(13) and controlled for GA (23–24, 25–26, 27 weeks) to evaluate protein-BPD relationships
at each time point (Days 1, 7 and 14).
We evaluated the antecedents of lung injury in the order they occur by creating time-
oriented logistic regression models that first considered endogenous characteristics of the
infant (e.g., GA and birth weight Z-score). Then we sequentially added information
conveyed by variables for an elevated concentration of each protein in the temporal order
the blood was collected. In one model, mechanical ventilation was added at Day 7 if the
infant was being treated with any form of mechanical ventilation on that day. In these time-
oriented models, significant variables (p < 0.01) are retained for inclusion in the model with
information from the next time interval or epoch. The final model included variables from
each of the three specimen collection intervals. We used a step down procedure seeking a
parsimonious solution without interaction terms.
Results
During the study period, 1249 mothers of 1506 infants consented to participate in the
ELGAN Study. Among these infants, 255 died before 36 weeks PMA and 51 died between
36 weeks PMA and two years adjusted age (Figure 1). An additional 258 were excluded
from our study because either follow-up evaluation was incomplete or blood specimens
were not available. Our cohort included the remaining 932 infants. Frequency of maternal,
pregnancy and newborn features within each category are listed in Table 1. Four hundred
infants (43%) were oxygen dependent but not ventilator dependent at 36 weeks PMA, and
an additional 86 infants (9%) were both oxygen and ventilator dependent.
Among the 258 infants who survived to 24 months adjusted age, but for whom
measurements of proteins were not available, the incidence of mild/moderate BPD was 39%,
and the incidence of severe BPD was 5%. Among the 51 infants who died between 36 weeks
PMA and 24 months adjusted age the incidence of mild/moderate BPD and severe BPD was
39% and 47%, respectively.
Protein measurements were available for 855 infants on Day 1, 860 infants on Day 7 and
781 infants on Day 14. Among all infants, concentrations of most proteins tended to increase
with advancing postnatal age (data not shown). In multinomial analysis, infants who
developed mild/moderate BPD, compared to infants with no BPD, had elevated Day 1
concentrations of TNF- α, elevated Day 7 concentrations of TNF-R2, MCP-1, and ICAM-1,
and elevated Day 14 concentrations of IL-1b, IL-6, TNF- α, TNF-R1, IL-8, MCP-1,
Bose et al. Page 4













ICAM-1, and MMP-9 (Table 2). In contrast, these infants had concentrations of RANTES
that were significantly reduced on Days 7 and 14 and MIP-1β on Day 7.
Compared to infants with no BPD, infants who developed severe BPD did not have an
appreciable inflammation signal in their Day 1 blood (Table 2). Rather, the signal was first
evident in Day 7 blood with elevated concentrations of TNF-R2, MCP-1, and ICAM-1. The
inflammation signal was even more apparent on Day 14 with elevated concentrations of
IL-6, TNFα, TNF-R1, MCP-1, ICAM-1, E-selectin1 and MMP-9. Severe BPD was also
preceded by reduced concentrations of RANTES (Days 7 and 14) and MMP-1 (Days 1 and
14).
We created three time-oriented risk models for the two BPD severity levels. All included
GA in three strata (23–24, 25–26, 27 weeks); the second also included birth weight Z-score
< −1 and the third included birth weight Z-score < −1 and mechanical ventilation on Day 7.
These models were created to identify the influence of fetal growth restriction and
mechanical ventilation on blood protein concentrations. Acquired sepsis and receipt of
postnatal steroids did not predict BPD nor did their addition change the proteins selected in
the modeling process.
Time-oriented risk model with Gestational Age Only (Table 3)
In this model, increased risk of mild/moderate BPD was associated with an elevated
concentration of TNF-α on Day 1. An elevated concentration of TNF-R2 on Day 7 was also
associated with increased risk, whereas infants who had elevated concentrations of
RANTES and MIP-1β on Day 7 were at reduced risk. The Day 7 RANTES risk information
was diminished by the addition of Day 14 RANTES information. IL-1β and ICAM-1 were
the two Day 14 proteins whose elevated concentrations provided supplemental information
about an increased risk of the mild/moderate BPD.
Elevated concentrations of VCAM-1 on Day 1 were associated with an increased risk of
severe BPD, while elevated concentrations of MMP-1 on Day 1 were associated with
decreased risk. Both of these proteins continued to convey information about risk even when
the information conveyed by Day 7 and Day 14 proteins was added to the model. Elevated
concentrations of Day 7 ICAM-1 and MCP-1 were associated with increased risk, whereas
increased concentrations of RANTES were associated with reduced risk. The risk
information provided by the RANTES Day 7 concentrations was diminished by the addition
of Day 14 RANTES concentrations to the model. Similarly, the association with Day 7
ICAM-1 concentrations was attenuated when the Day 14 ICAM-3 concentrations were
added to the model.
Time-oriented risk model with Gestational Age and Birth Weight Z-score < −1 (Table 4)
Birth weight Z-score < −1 predicted both mild/moderate and severe BPD in all epochs even
after adjustment for GA and protein levels. The inclusion of birth weight Z-score resulted in
relatively minor changes in the Day 1 protein levels that had been identified as predictors in
the model that excluded birth weight Z-score. TNF-α remained in the model, as did
RANTES on Day 14, but RANTES on Day 7 did not. The predictors of severe BPD changed
minimally. ICAM-1 was not added on Day 7 as it had been in the previous model, while on
Day 14, ICAM-1 replaced ICAM-3.
Time-oriented risk model with Gestational Age, Birth Weight Z-score < −1 and Mechanical
Ventilation on Day 7 (Table 5)
Mechanical ventilation on Day 7 was a predictor of both mild/moderate and severe BPD and
was a stronger predictor of severe BPD than all other risk factors, including protein levels.
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Adjusting for mechanical ventilation on Day 7 altered the model for mild/moderate BPD by
dropping ICAM-1 on both Days 7 and 14, and RANTES on Day 14. Adjusting for
mechanical ventilation altered the model for severe BPD by eliminating RANTES on both
Days 7 and 14, and MCP-2 on Day 7. ICAM-1 on Day 14 was replaced by ICAM-3.
Discussion
Our study demonstrates that the risk of BPD among infants born before the 28th week of
gestation is associated with elevated blood concentrations of a variety of proteins integral to
inflammation. These include pro-inflammatory cytokines, adhesion molecules and proteases.
Reduced risk is prominently associated with increased concentrations of one chemokine,
RANTES. These findings suggest that an inflammatory process involving a variety of
mediators is critical in the development of BPD. Elevations of inflammatory proteins
associated with BPD risk occur during the first days following birth. However, inflammation
intensifies thereafter. Therefore, exposures that promote inflammation after the first
postnatal days may be more critical in the development of BPD.
Our observations are in general agreement with previous reports. For example, in a cohort of
ELGANs, death or BPD at 36 weeks PMA was predicted by elevated blood concentrations
of a variety of cytokines (7). The notable similarities to our findings were the increased risk
associated with high levels of TNFα and decreased risk with high levels of RANTES. In
contrast to that study, we did not find a distinct pattern of decreased concentrations of
proteins that the authors associated with adaptive (as opposed to innate) immunity in infants
who developed BPD, with the exception of RANTES. Our choice of proteins might have
masked these trends. For example, we did not measure IFNγ or TNFβ, cytokines associated
with innate immunity, or IL-10, a cytokine associated with adaptive immunity (14). A more
important difference between these studies might be our exclusion of infants who died prior
to 36 weeks PMA. In some studies of BPD, death prior to 36 weeks PMA is included as an
outcome measure because it competes with BPD. However, because a relatively small
proportion of infants die from lung disease, and some die of multi-system organ failure or
sepsis, processes with a strong systemic inflammatory component, we believe that it is more
appropriate to exclude infants who die prior to 36 weeks PMA when investigating the role of
inflammation in lung disease.
We observed a doubling of risk of less severe BPD among infants with concentrations of
TNFα in the highest quartile on the first postnatal day. A similar association was not seen in
another cohort of premature infants (15). Several important differences in study design
might explain this lack of agreement. For example, that study included infants born before
the 33rd week of gestation, while our study did not include any infant born between weeks
28 to 32. The differences may also have resulted from different methods to account for the
potential contribution of chorioamnionitis. We did not adjust for the presence of
chorioamnionitis in our regression models because in a previous study of BPD risk in this
cohort, we did not identify chorioamnionitis as a risk factor (16). In addition, that study
measured concentrations in cord blood only, while the specimens in our study were obtained
postnatally. In both humans and animals, pro-inflammatory cytokines appear in the lungs
soon after early neonatal exposures (e.g. mechanical ventilation) that promote inflammation
(17, 18), raising the possibility that the early elevations in TNFα in our infants are a
consequence of postnatal exposures.
The chemokine RANTES was one of the few proteins associated with reduced risk of both
mild/moderate and severe BPD. As a chemotactic agent it attracts inflammatory cells to the
site of infection or injury (19). Therefore, one might expect elevated levels to intensify the
inflammatory process and increase the likelihood of BPD. In fact, elevated levels of other
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chemotactic agents, including IL-8 and MIP-1, have been observed in bronchial alveolar
lavage fluid in infants who develop BPD (20). However, there is evidence that RANTES
actually protects against organ damage in animal models of inflammation-mediated diseases
(21, 22). In addition, an in vitro study provides support that RANTES reduces inflammation
(23). Thus the association of reduced risk with elevated concentrations of RANTES might
reflect anti-inflammation and protection.
Other proteins highly associated with both mild/moderate and severe BPD are adhesion
molecules, most notably ICAM-1 and ICAM-3. As a group, adhesion molecules promote
migration of inflammatory cells from the blood to sites of injury in the lung, and their
primary site of action is at the blood-tissue interface (24). Because of this site of action,
blood levels of adhesion molecules might be elevated in organ-specific inflammation.
Therefore, it is not surprising that increased concentrations in blood are also associated with
BPD risk. Other circulating inflammatory proteins that are elevated in BPD may not be of
pulmonary origin. Rather, their presence may result from a systemic response to injury or
inflammation in the lung (e.g., SAA or CRP). It is also possible that under certain
circumstances proteins produced by cells in the lung remain in the lung compartment, while
under other circumstances (e.g., intense pulmonary inflammation), they may “leak” into the
circulation (25). Because of these uncertainties, we advise caution in drawing inferences
about the observed changes in blood proteins and pulmonary pathology.
Some important observations resulted from developing time-oriented risk models for BPD
that both included and excluded specific, known clinical risk factors. In one model, we
included birth weight Z-score, a marker of fetal growth restriction, because it is both a
known BPD risk factor (16, 26) and is associated with decreased placental expression of
selected inflammatory cytokines (27). The associations between protein concentrations and
BPD risk in this model were similar to those in the model that excluded birth weight Z-
score. This finding suggests that the increased BPD risk associated with fetal growth
restriction is probably not mediated by circulating inflammation-associated proteins. By
contrast, the addition of mechanical ventilation at 7 days changed the apparent influence of
ICAM-1 and RANTES, suggesting that mechanical ventilation may influence pathogenesis
by altering expression of these proteins.
This study has a number of strengths. We included a large number of infants, making it
unlikely that we missed important associations due to lack of statistical power, and we
collected all of our data prospectively. We selected infants based on GA, not birth weight, in
order to minimize confounding due to factors related to fetal growth restriction, and with
regression models we adjusted for fetal growth restriction. We did not include infants who
died prior to 36 weeks PMA, thereby restricting this to a study of BPD and not the
composite outcome of BPD or death.
This study also has limitations. For practical reasons, our cohort was limited to infants who
had complete neurodevelopmental evaluation at 24 months. This resulted in the non-random
exclusion of two potentially important cohorts. The incidence of both mild/moderate and
severe BPD in the cohort of infants who survived to 24 months but for whom protein
measurements were not available was only slightly lower than in our study cohort.
Therefore, their exclusion is not likely to have resulted in a significant bias in the results.
The incidence of severe BPD among infants who died between 36 weeks PMA and 24
months was significantly higher (47%) than in our study cohort (9%). The effect of
exclusion of these infants, however, is likely to be minimal because they represent a small
proportion of the ELGAN Study cohort (≈ 4%). The diagnosis of BPD was made on the
basis of clinicians’ decisions to treat with mechanical ventilation or supplemental oxygen,
not on the basis of physiologic disturbances, and clinical practices almost certainly varied
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among centers. Finally, because this was an observational study, we cannot know whether
the protein elevations were associated with BPD in a cause and effect relationship or
whether the elevations are surrogates for other processes that might have influenced BPD
risk.
Our study has several implications for researchers interested in preventing BPD. First, the
different risk factor profile for mild/moderate and severe BPD suggest that BPD is a
heterogenous condition. Consideration of this heterogeneity could lead to more informative
epidemiologic studies. Second, our findings suggest the possibility that inflammation-
associated proteins in neonatal blood could serve as biomarkers of modifiable biological
processes involved in the development of BPD. If so, these biomarkers could be used as
response measures in intervention studies. Third, at least some aspect of the fetal and
neonatal inflammatory response is associated with a lower risk of BPD. Thus one approach
to prevention might be the enhancement of endogenous protectors.
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Table 3
Odds ratios (and 99% confidence intervals) of mild/moderate BPD and severe BPD (vs no BPD) and
associated with a concentration of the protein on the left in the highest quartile for gestational age and day
blood was obtained relative to the risk among infants whose concentration was in the lower 3 quartiles. These
are time-oriented logistic risk models that include gestational age (23–24, 25–26, 27 weeks).
Model for Mild/Moderate BPD
Day Protein Day 1 Days 1 and 7 Days 1, 7, 14
1 GA 23–24 6.4 (3.7, 12) 7.8 (4.1, 15) 9.2 (4.5, 19)
GA 25–26 2.5 (1.6, 3.9) 2.7 (1.6, 4.3) 2.9 (1.7, 5.0)
TNF-α 1.8 (1.2, 2.8) 2.1 (1.3, 3.3) 2.0 (1.2, 3.5)
7 RANTES 0.6 (0.4, 0.9) 0.7 (0.4, 1.2)
TNF-R2 2.1 (1.3, 3.5) 1.8 (1.03, 3.3)
MIP-1β 0.5 (0.3, 0.8) 0.5 (0.3, 0.9)
14 IL-1β 2.0 (1.2, 3.4)
RANTES 0.5 (0.3, 0.9)
ICAM-1 2.8 (1.6, 5.0)
Model for Severe BPD
Day Protein Day 1 Days 1 and 7 Days 1, 7, 14
1 GA 23–24 9.0 (3.3, 24) 11 (3.5, 32) 15 (3.8, 60)
GA 25–26 3.0 (1.3, 7.2) 3.0 (1.2, 7.7) 5.1 (1.6, 16)
VCAM-1 2.5 (1.1, 5.4) 3.2 (1.3, 7.6) 3.8 (1.3, 11)
MMP-1 0.3 (0.1, 0.9) 0.4 (0.1, 0.98) 0.2 (0.1, 0.9)
7 ICAM-1 2.4 (1.1, 5.3) 1.6 (0.6, 4.2)
MCP-1 2.3 (1.1, 5.0) 2.9 (1.1, 7.3)
RANTES 0.3 (0.1, 0.7) 0.5 (0.1, 1.7)
14 RANTES 0.3 (0.1, 0.9)
ICAM-3 9.0 (3.3, 25)
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Table 4
Odds ratios (and 99% confidence intervals) of mild/moderate BPD and severe BPD (vs no BPD) and
associated with a concentration of the protein on the left in the highest quartile for gestational age and day
blood was obtained relative to the risk among infants whose concentration was in the lower 3 quartiles. These
are time-oriented logistic risk models that include gestational age (23–24, 25–26, 27 weeks) and birth weight
Z-score <−1.
Model for Mild/Moderate BPD
Day Protein Day 1 Days 1 and 7 Days 1, 7, 14
1 GA 23–24 7.5 (4.1, 13) 8.3 (4.4, 16) 9.5 (4.7, 19)
GA 25–26 2.5 (1.6, 4.0) 2.8 (1.6, 4.4) 2.9 (1.7, 5.0)
BWZ* < −1 3.1 (1.8, 5.4) 2.8 (1.5, 4.9) 2.1 (1.1, 4.0)
TNF-α 1.8 (1.2, 2.9) 1.9 (1.2, 3.1) 2.0 (1.2, 3.4)
7 ICAM-1 1.9 (1.2, 3.2) 1.5 (0.9, 2.7)
MIP-1β 0.5 (0.3, 0.8) 0.5 (0.3, 0.9)
14 ICAM-1 2.7 (1.5, 5.0)
IL-1β 1.9 (1.2, 3.2)
RANTES 0.5 (0.3, 0.8)
Model for Severe BPD
Day Protein Day 1 Days 1 and 7 Days 1, 7, 14
1 GA 23–24 9.9 (3.5, 28) 13 (4.1, 39) 18 (4.3, 78)
GA 25–26 2.8 (1.1, 6.8) 2.8 (1.1, 7.2) 4.9 (1.5, 16)
BWZ < −1 4.6 (2.0, 11) 4.3 (1.8, 11) 4.2 (1.4, 12)
VCAM-1 2.7 (1.2, 6.1) 3.7 (1.5, 9.0) 4.5 (1.5, 13)
MMP-1 0.3 (0.1, 0.9) 0.4 (0.1, 0.98) 0.2 (0.1, 0.9)
7 RANTES 0.3 (0.1, 0.9) 0.6 (0.2, 2.2)
MCP-1 2.6 (1.2, 5.7) 3.2 (1.2, 8.3)
14 ICAM-1 10 (3.8, 28)
RANTES 0.2 (0.1, 0.8)
*
BWZ = birth weight Z-score
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Table 5
Odds ratios (and 99% confidence intervals) of mild/moderate BPD and severe BPD (vs no BPD) of the protein
on the left and associated with a concentration of the protein on the left in the highest quartile for gestational
age and day blood was obtained relative to the risk among infants whose concentration was in the lower 3
quartiles. These are time-oriented logistic risk models that include gestational
age (23–24, 25–26, 27 weeks), birth weight Z-score <1 and mechanical ventilation on Day 7.
Model for Mild/Moderate BPD
Day Protein Day 1 Days 1 and 7 Days 1, 7, 14
1 GA 23–24 7.5 (4.1, 13) 4.1 (2.1, 8.3) 5.6 (2.6, 12)
GA 25–26 2.5 (1.6, 4.0) 1.9 (1.1, 3.2) 2.1 (1.2, 3.8)
BWZ*< −1 3.1 (1.8, 5.4) 2.4 (1.3, 4.5) 2.0 (1.02, 3.9)
TNF-α 1.8 (1.2, 2.9) 2.1 (1.3, 3.5) 2.0 (1.2, 3.5)
7 Mech vent** 4.2 (2.6, 6.9) 2.9 (1.7, 5.1)
TNF-R2 2.2 (1.3, 3.9) 2.1 (1.1, 3.9)
SAA 0.5 (0.3, 0.9) 0.5 (0.3, 0.9)
MIP-1β 0.5 (0.3, 0.9) 0.6 (0.3, 1.02)
14 IL-1β 1.9 (1.1, 3.2)
ICAM-3 2.4 (1.3, 4.4)
Model for Severe BPD
Day Protein Day 1 Days 1 and 7 Days 1, 7, 14
1 GA 23–24 9.9 (3.5, 28) 4.3 (1.3, 13) 5.0 (1.3, 19)
GA 25–26 2.8 (1.1, 6.8) 1.8 (0.7, 4.8) 2.4 (0.9, 7.6)
BWZ < −1 4.6 (2.0, 11) 3.8 (1.5, 9.4) 3.0 (1.1, 8.1)
VCAM-1 2.7 (1.2, 6.1) 4.1 (1.6, 11) 4.0 (1.4, 12)
MMP-1 0.3 (0.1, 0.9) 0.4 (0.1, 0.98) 0.2 (0.1, 0.9)
7 Mech vent 15 (4.2, 56) 11 (2.7, 50)
14 ICAM-3 5.6 (2.2, 14)
*
BWZ = birth weight Z-score
**
Mech vent = mechanical ventilation
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